

Metabolica Meal Replacement: A Metabolically Targeted Nutritional Support Formula for Cancer Patients

Dr. Steve Rallis, DC, ND

Chief Medical Officer, Rallis Wellness Inc.

Product Developers: Dr. Steve Rallis, DC, ND, Nick Rallis, B. Comm., JD (cand.), Marcus Rallis, GBDA (cand.)

Intended Use: For Clinical Education and Marketing/Investor Relations

Abstract

Metabolica Meal Replacement is a nutritionally precise formula designed to meet the complex metabolic demands of cancer patients during treatment, recovery, and survivorship. Traditional shakes focus on calorie replacement, often using sugars, dairy proteins, and omega-6 oils that activate insulin/IGF-1, mTOR, and inflammatory pathways.

Metabolica's design takes the opposite approach: providing balanced, physiologic nutrition that nourishes healthy cells and supports healthy cellular metabolism, while avoiding substrates that can fuel tumor growth.

The formula strategically minimizes substrates known to activate glucose–insulin signaling, glutaminolysis, and IGF-1/mTOR anabolic pathways, while emphasizing fat- and ketone-based energy, which supports mitochondrial function, reduces oxidative stress, and promotes metabolic flexibility in normal tissues.

Its dual **plant-protein system** (rice + pea) delivers adequate nitrogen with lower lysine and glutamine content, minimizing anabolic drive. Medium-chain triglycerides (MCTs) and exogenous β -hydroxybutyrate (BHB) salts supply efficient, non-glycemic energy.

Equally important is our formula's **micronutrient engineering**, which extends far beyond simple “daily value” considerations. Cancer biology demonstrates that certain trace minerals can

function as growth accelerants. Two simple examples of this would be copper and iron. Copper, is a known cofactor in angiogenesis and tumor invasion, while iron can amplify oxidative stress and feed tumor proliferation. Consequently, both were intentionally excluded from our formula.

Conversely, other micronutrients—such as vitamin B12, zinc, and selenium—are essential for host immune function, redox balance, and DNA repair, but can stimulate growth when provided in excess. Metabolica includes physiologic levels of these nutrients –enough to maintain healthy metabolism, but not enough to actively proliferate angiogenic pathways.

Every micronutrient and botanical was further evaluated for nutrient–drug interactions, radiation synergy or antagonism, ROS modulation, and effects on hepatic and renal clearance, ensuring compatibility with chemotherapy, radiation, immunotherapy, and peri-operative protocols. This includes avoidance of high-dose antioxidants during active treatment, as well as exclusion of compounds known to interfere with drug metabolism (e.g., CYP450 modulators at clinically relevant doses).

Because cancer therapies aggressively target rapidly dividing cells—including the enterocytes that line the gastrointestinal tract—digestive disturbances are exceedingly common. In our clinical work with oncology patients, it became clear that any metabolic support formula must also provide GI support, tolerance, and soothing. For this reason, Metabolica includes a blend of digestive enzymes and targeted botanicals designed not only to enhance macronutrient absorption, but also to deliver gentle, demulcent support to irritated mucosal tissues. The selected fiber, agave inulin, paired with monk fruit, cinnamon, and natural vanilla, creates a pleasant flavor profile and balanced sweetness while maintaining strict glycemic control.

Collectively, these strategies define Metabolica as a state-of-the-art, **precision-engineered nutrition system** that provides comprehensive, safe, metabolically intelligent support for patients navigating the demands of cancer treatment and recovery.

Table of Contents

- 1. Metabolic Rationale & Mechanistic Targets**
- 2. Comparative Analysis — Metabolica vs Leading Meal Replacements**
- 3. Clinical Applications & Use Protocols**
- 4. Scientific Discussion & Mechanistic Overview**
- 5. Summary, Safety & Clinical Positioning**
- 6. References**

Section 1 – Metabolic Rationale & Mechanistic Targets

Overview

Metabolica Meal Replacement is formulated to address the unique metabolic vulnerabilities of cancer patients undergoing treatment or recovery.

Conventional high-protein or high-carbohydrate supplements often ignore the altered metabolism of malignant and host tissues.

Metabolica's macronutrient ratio is designed to *nourish and protect normal tissue* while avoiding stimulation of growth pathways driven by glucose, glutamine, and insulin-like growth factor 1 (IGF-1).

The formulation aligns with the principles of **metabolic oncology**, targeting two dominant fuel sources for proliferative tumor metabolism — **glucose** and **glutamine** — while supporting cellular resilience through **fat- and ketone-based energy**.⁴

1. Glucose Restriction and Insulin–IGF-1 Axis Modulation

Why This Matters:

Most commercial meal replacements rely on maltodextrin, sugar, or dairy proteins as major ingredients.

These ingredients acutely raise glucose and insulin, activating the **IGF-1 / mTOR** axis that promotes anabolic cell growth and suppresses autophagy.

Chronic activation of these pathways correlates with tumor proliferation and reduced treatment response.

Metabolica's Approach:

Metabolica removes all simple sugars and maltodextrin, relying instead on

- **Organic agave inulin** – A low-glycemic prebiotic fiber that supports microbiome balance and short-chain fatty acid (SCFA) production.⁶

- **Monk fruit extract** – A zero-glycemic natural sweetener that does not stimulate insulin secretion and exhibits potential anti-inflammatory properties.⁷
- **Medium-chain triglycerides (MCTs) and β -hydroxybutyrate (BHB) salts** – These provide clean, ketone-based energy that bypasses glycolytic pathways.⁸

This composition minimizes insulinogenic signaling, creating a metabolic environment supportive of *healthy cellular efficiency* rather than tumor growth.

2. Glutamine and Protein Modulation

Why This Matters:

Glutamine acts as a secondary fuel for many tumors, driving the TCA cycle through glutaminolysis.⁹

Animal proteins (high in leucine and lysine) are potent mTOR activators.¹⁰

Ensure® and Boost® rely on milk proteins (casein, whey) that elevate serum IGF-1 and supply abundant BCAAs. In cancer patients, this may inadvertently support a pro-growth state.¹¹

Metabolica's Approach:

- **Dual plant-protein system (rice + pea)** – This blend supplies all essential amino acids with lower leucine and methionine content compared to dairy, reducing anabolic drive while preventing muscle wasting.¹²
-
- **Moderate total protein (\approx 15 g per serving)** – adequate for tissue maintenance but below mTOR-activation threshold.
- **Unique protein-to-fat ratio** prioritizes preservation, not hypertrophy.
- **Proteolytic enzymes** – proteases, lipase, and carbohydrase enhance digestion and tolerance in compromised GI tracts.

Result: Support of lean tissue integrity without fueling tumor-associated nitrogen metabolism.

3. Lipid and Ketone-Based Metabolism

Why This Matters:

Fatty-acid oxidation and ketone utilization provide efficient, low-inflammatory energy for healthy cells while depriving many tumors of preferred glycolytic substrates.

Ketones like BHB exhibit anti-inflammatory and anti-proliferative effects (Poff et al., *Front Nutr.*, 2021).

Metabolica's Approach:

- **MCTs (C8/C10)** and **BHB salts (Na, K, Mg, Ca forms)** promote mitochondrial efficiency.
- Lower oxidative stress + systemic inflammation.
- Encourage mild, physiologic nutritional ketosis → enhanced metabolic flexibility.

4. Inflammation and Redox Modulation

Metabolica integrates bioactives that regulate inflammation and oxidative stress:

- **Berberine** – activates AMPK, suppresses mTOR, improves insulin sensitivity (Zhang et al., *Biochem Pharmacol.*, 2020).
- **Cinnamon extract** – enhances insulin receptor sensitivity.
- **Ginger root extract** – reduces IL-6 and TNF- α , alleviates nausea.
- **Deglycyrrhizinated licorice (DGL)** – soothes gastric mucosa.

5. Micronutrient Balance and Physiologic Dosing

Metabolica delivers **physiologic micronutrient levels**, not pharmacologic doses:

- Supports metabolic function without overstimulation of growth signals.

- Avoids **iron, copper, and high B12**, which can potentiate oxidative stress and angiogenesis (Finch 2018; Zhang 2021).
- Provides magnesium, zinc, selenium, and manganese at optimal co-factor levels for antioxidant and DNA-repair enzymes.

6. Digestive Support and Patient Tolerance

Digestive intolerance is common during cancer therapy. Metabolica includes:

- **Proteases + lipase + carbohydrase** → improved nutrient absorption.
- **Ginger & DGL** → soothing gastric mucosa.
- **Agave inulin** → prebiotic fiber for microbiome health.

These enhance tolerability compared with lactose- or maltodextrin-containing formulas.

Summary Table – Mechanistic Overview

Metabolic Target	Conventional Risk Factor	Metabolica Strategy	Primary Mechanism
IGF-1 / mTOR	Milk proteins, leucine excess	Plant proteins low in lysine & methionine	↓Anabolic signaling
Glycolysis / Warburg Effect	Sugars, maltodextrin	Low-carb, MCT, BHB	↑Ketone metabolism
Inflammation	Omega-6 oils	MCT + berberine + ginger	↓ NF-κB activity

Oxidative Stress	Iron, copper, B12 excess	Controlled micronutrients	↓ROS generation
Digestive Tolerance	Casein, soy isolates	Enzymes + DGL + ginger	↑ GI comfort

Section 2 – Comparative Analysis: Metabolica vs. Leading Meal Replacements

Overview

Most commercial meal replacements for cancer or general nutrition are formulated around **calorie density and palatability**, not metabolic compatibility.

Popular products like **Ensure® Plus** and **Boost® High Protein** were designed decades ago for general malnutrition and recovery, not the altered metabolic landscape of cancer.

These conventional formulas can inadvertently activate **insulin/IGF-1** and **mTOR** pathways, enhance **glycolytic metabolism**, and increase **systemic inflammation**—conditions that may undermine metabolic stability during therapy.

Metabolica was developed as a metabolically aligned alternative—providing energy and nutrition that support *the host*, not the tumor microenvironment.

2.1 Comparative Ingredient Overview

Product	First 5 Ingredients	Primary Protein Source	Sugar (g/serving)	Fat Source	Metabolic Considerations (Scientific Basis)
Ensure® Plus	Water, Corn Maltodextrin, Sugar, Milk Protein Concentrate, Canola Oil	Casein/Whey	22 g	Canola & Corn Oils	High glycemic load; dairy proteins increase IGF-1/mTOR; omega-6 fats promote inflammation (Levine 2014; Giovannucci 2019).
Boost® High Protein	Water, Glucose Syrup, Milk Protein Concentrate, Sugar, Soy Oil	Casein/Whey	20 g	Soy & Canola Oil	Rapid insulin/IGF-1 response; soy oil omega-6 dominance; dairy proteins stimulate anabolic signaling (Ravasco 2020).
Metabolica	Rice Protein, MCT (C8/C10), Organic Pea Protein, Agave Inulin, β-Hydroxybutyrate Salts	Rice + Pea	0 g	MCT (C8/C10)	Low glycemic; supports ketone metabolism; anti-inflammatory fat profile; no dairy, sugar, or maltodextrin.

2.2 Glycemic and Insulinogenic Load

High-carbohydrate shakes depend on **maltodextrin or glucose syrup**, both with glycemic indices above 85.

These rapidly elevate glucose and insulin, activating mTOR and accelerating cellular proliferation (Levine 2014; Klement 2017).

Metabolica employs a different energy paradigm:

- **Agave inulin (GI \approx 1)** – stabilizes glycemia and supports beneficial gut flora.
- **Monk fruit extract** – zero-glycemic, natural sweetness.
- **β -Hydroxybutyrate salts (BHB)** – provide alternate oxidative fuel.

This yields a near-zero glycemic load while maintaining steady-state energy production.

2.3 Protein Source and Anabolic Signaling

Animal vs. Plant Proteins

Dairy-based proteins (casein, whey) are among the most **anabolic** due to their leucine and lysine content.

While beneficial for athletic populations, in oncology they may upregulate **IGF-1** and **mTOR** activity, promoting anabolic signaling (Newsholme 2020; Ravasco 2020).

Metabolica's solution:

- **Rice + pea protein blend** supplies complete amino acids with lower lysine/methionine → limits anabolic drive.
- **Moderate protein** (~15 g per serving) supports tissue integrity without excess nitrogen load.
- **Digestive enzymes** ensure efficient utilization and reduce GI distress.

Result: Maintenance of lean mass without promoting tumor-favorable metabolism.

2.4 Lipid Composition and Inflammation

Omega Balance and Energy Efficiency

Most commercial formulas use **canola, soy, or corn oils**, which are rich in omega-6 linoleic acid—precursors to **prostaglandin E2 (PGE2)** and inflammatory cytokines (De Lorgeril 2018).

Metabolica uses **medium-chain triglycerides (MCTs)** exclusively as its fat source:

- Rapidly absorbed and converted to ketones.
- Do not contribute to adipose storage.
- Exhibit anti-inflammatory and mitochondrial-supportive effects (Poff 2021).

This lipid profile supports sustained cellular energy while minimizing systemic inflammation.

2.5 Micronutrient Density and Physiologic Dosing

Parameter	Conventional Formulas (Ensure/Boost)	Metabolica Design
Iron	8–10 mg	0.8 mg — avoids iron-driven oxidative stress (Finch 2018).
Vitamin B12	6–12 µg	2.4 µg — physiologic level, avoids angiogenic signaling (Zhang 2021).
Copper	0.8–1.0 mg	Not added — prevents copper-mediated angiogenesis (Van Ginderachter 2019).
Antioxidant Vitamins	Often supraphysiologic	Balanced 50% DV — supports antioxidant systems without redox imbalance.
Selenium & Zinc	Variable	Physiologic (11 µg Se, 5 mg Zn) — maintains enzymatic antioxidant defense.

This balance avoids the nutrient excesses that can perturb redox homeostasis or stimulate proliferation.

2.6 Digestive Tolerance and Absorption

Digestive intolerance—bloating, diarrhea, nausea—is a frequent complaint with conventional formulas.

Lactose, soy isolates, and emulsifiers are common irritants.

Metabolica mitigates these issues via:

- **Digestive enzyme blend** (protease, lipase, carbohydrase).
- **Ginger and DGL extracts** for gastric soothing and anti-nausea effects.
- **Inulin prebiotic fiber** for microbiome support.

This ensures consistent absorption and comfort even during chemotherapy or GI-sensitive states.

2.7 Summary Comparison Table

Parameter	Ensure® Plus	Boost® High Protein	Metabolica
Energy Source	Sugar + Maltodextrin	Glucose + Sugar	MCT + BHB + Inulin
Protein Source	Casein/Whey	Casein/Whey	Plant (Rice + Pea)
Glycemic Index	High (>70)	High (>65)	Very Low (<15)
Sugar (g)	22	20	0
Dairy Free	X	X	✓
Ketogenic Support	X	X	✓
Inflammatory Oils	Canola/Corn	Soy/Canola	None (MCT only)
Iron/Copper Added	Yes	Yes	Controlled/Excluded
Digestive Enzymes	None	None	Included

Interpretive Summary

Metabolica represents a paradigm shift in therapeutic nutrition—from simply supplying calories to restoring **metabolic balance**.

Its low-glycemic, plant-protein, and fat-centric design aligns with evidence that moderating **insulin/IGF-1, glutamine flux, and inflammatory signaling** can improve metabolic resilience during cancer care.

By eliminating sugars, dairy proteins, and omega-6 oils, Metabolica delivers nutritionally complete yet metabolically conservative support for oncology patients.

Section 3 – Clinical Applications and Use Protocols

Overview

Metabolica supports patients across all phases of cancer care — from active treatment to surgical recovery and long-term remission.

Each stage presents unique metabolic challenges, including mitochondrial fatigue, inflammation, insulin resistance, and digestive intolerance.

Unlike conventional high-sugar or dairy-based formulas, Metabolica provides **targeted metabolic support** through balanced macronutrients and physiologic micronutrient dosing, maintaining energy stability without stimulating growth signaling pathways.

3.1 During Chemotherapy or Radiation

Metabolic Context

Chemotherapy and radiation impose oxidative and metabolic stress, elevating inflammatory cytokines (IL-6, TNF- α) and disrupting glucose tolerance.

High-carbohydrate nutritional formulas exacerbate hyperglycemia and **IGF-1/mTOR activation**, worsening fatigue and inflammation.

Metabolica's Supportive Role

- **MCTs + BHB salts** provide efficient, non-glycemic energy for healthy cells.
- **Plant proteins (rice + pea)** preserve lean tissue with low glutamine content.
- **Physiologic micronutrients** (Mg, Se, Zn) enhance mitochondrial enzymes and antioxidant defenses.
- **Berberine + cinnamon** improve insulin sensitivity and glycemic stability.
- **Ginger + DGL** mitigate nausea and improve tolerance.

Recommended Use

- **Serving:** 2–4 scoops daily (300–600 kcal).
- **Timing:** Mid-morning or mid-afternoon between meals or when appetite is reduced.
- **Preparation:** Mix with water or unsweetened nut milk; may blend with small amounts of low-GI fruit (e.g., berries).

Clinical Note: Metabolica may serve as a partial meal replacement on treatment days when solid intake is limited.

3.2 Pre-Surgical and Peri-Operative Nutrition

Metabolic Context

Surgical stress induces transient insulin resistance, catabolism, and inflammatory activation. Optimizing peri-operative nutrition improves wound healing and recovery (Weimann 2020).

Metabolica's Supportive Role

- Maintains **euglycemia** and minimizes peri-operative hyperglycemia.
- Supplies **rapidly absorbable MCT energy** without digestive burden.
- Provides **balanced amino acids** for tissue integrity without mTOR overstimulation.
- Delivers **micronutrients (A, D, E, K, Zn, Se)** for immune competence and collagen synthesis.

Recommended Use

- **Pre-Surgery (5–7 days prior):** 1-2 scoops daily within meals to optimize stores.
- **Post-Surgery:** 2-4 scoops daily as tolerated for recovery and appetite support.

Clinical Note: Free of dairy and maltodextrin, Metabolica reduces postoperative bloating and nausea.

3.3 Recovery and Remission Support

Metabolic Context

After treatment, patients frequently experience **mitochondrial inefficiency, fatigue, and sarcopenia**.

Long-term goals focus on restoring **metabolic flexibility** while maintaining low-inflammatory and low-IGF-1 states.

Metabolica's Supportive Role

- **Ketone-based energy** enhances endurance and cognitive clarity.
- **Low-glutamine, plant-based proteins** maintain muscle without anabolic excess.
- **Inulin fiber** repairs microbiome balance and gut-brain signaling.
- **Physiologic micronutrients** prevent both deficiency and toxic accumulation.

These elements collectively sustain remission by supporting balanced mitochondrial metabolism (Klement 2017; Seyfried 2019).

Recommended Use

- **Maintenance:** 1-2 scoops daily between meals or as meal replacement.
- **Enhanced energy:** Blend with extra-virgin, organic olive oil or other targeted functional foods for higher caloric density.

3.4 Digestive and Tolerance Considerations

Digestive issues such as bloating, nausea, and altered motility are frequent during therapy. Metabolica supports GI function via:

- **Digestive enzyme blend** → improved macronutrient absorption.
- **Ginger + DGL extracts** → reduced mucosal irritation and nausea.
- **Inulin prebiotic** → supports *Bifidobacterium* and *Lactobacillus* populations.

- **Absence of lactose, gluten, soy, and emulsifiers** → reduces intolerance reactions.

3.5 Clinical Summary Table

Stage of Care	Metabolic Challenge	Metabolica Mechanism	Clinical Goal
Chemotherapy / Radiation	Glucose dependency, mitochondrial fatigue	MCT + BHB → non-glycemic energy	Preserve energy & lean mass
Pre-Surgery	Insulin resistance, inflammation	Low-glycemic, balanced amino acids	Optimize metabolic readiness
Post-Surgery	Wound healing, GI intolerance	MCT + enzymes + micronutrients	Support recovery & gut function
Remission	Chronic inflammation, inflexibility	Ketones + balanced protein/fat	Maintain long-term metabolic health

Interpretive Summary

Metabolica represents a **metabolically aligned nutritional adjunct** for oncology and recovery care.

Its low-glycemic, fat-forward formulation and physiologic micronutrient profile nourish the patient while avoiding substrates that feed tumor metabolism.

This integrative design supports stable energy, improved tolerance, and resilient recovery—*feeding the person, not the cancer.*

Section 4 – Scientific Discussion & Mechanistic Overview

4.1 Introduction

Cancer is both a **genetic and metabolic disease**, characterized by disrupted energy regulation and mitochondrial inefficiency.

Tumor cells display **metabolic inflexibility**, relying on glucose and glutamine to fuel growth while avoiding oxidative phosphorylation—a hallmark known as the **Warburg effect**.

This dysregulation offers a therapeutic window. By modulating nutrient availability and energy sources, nutrition can influence cancer metabolism.

Metabolica is designed to target these biochemical pathways by reducing glucose and glutamine availability and enhancing fat- and ketone-based energy metabolism.

4.2 IGF-1 and mTOR Signaling Modulation

Mechanistic Background

The **IGF-1/mTOR** axis governs cellular growth and nutrient sensing. Elevated IGF-1—often driven by dairy and high-animal-protein diets—activates mTOR, stimulating proliferation and angiogenesis while suppressing autophagy (Levine 2014).

Metabolica's Mechanistic Impact

- **No dairy proteins:** avoids casein- and whey-induced IGF-1 elevations.
- **Moderate plant protein** (≈15 g) maintains tissue repair without anabolic excess.
- **Berberine** activates AMPK, indirectly inhibiting mTOR (Zhang 2020).
- **Magnesium and zinc** balance insulin sensitivity.

Result: Controlled nutrient signaling that supports recovery without promoting unchecked cell growth.

4.3 AMPK Activation and Metabolic Flexibility

Mechanistic Background

AMP-activated protein kinase (AMPK) regulates cellular energy status. When activated, AMPK promotes fat oxidation, mitochondrial biogenesis, and autophagy while inhibiting mTOR.

Metabolica's Mechanistic Impact

- **Berberine** acts as a natural AMPK activator.
- **BHB salts** increase NAD⁺/NADH ratio, enhancing oxidative metabolism.
- **MCTs** provide direct substrates for mitochondrial β -oxidation.

Outcome: Improved metabolic flexibility, allowing healthy cells to alternate between fat and glucose utilization—counteracting tumor glycolysis dependence.

4.4 Glycolysis and Glutaminolysis: Restricting Tumor Fuel Supply

Mechanistic Background

Tumor cells rely on **aerobic glycolysis** and **glutaminolysis** for rapid ATP and biosynthetic precursors. High glucose and glutamine availability sustain this state.

Metabolica's Mechanistic Impact

- **Zero added sugars/maltodextrin** → reduces glycolytic substrate load.
- **Plant proteins low in lysine/methionine** → moderate glutamine flux.
- **BHB salts** → serve as alternative oxidative fuel for normal cells, poorly metabolized by many tumors (Poff 2021).

Outcome: Controlled fuel availability that supports normal tissues but constrains tumor energetics.

4.5 Oxidative Stress, Inflammation, and the Tumor Microenvironment

Mechanistic Background

Reactive oxygen species (ROS) and pro-inflammatory cytokines (IL-6, TNF- α , CRP) promote angiogenesis and immune suppression.

Omega-6–dominant oils (corn, canola, soy) elevate prostaglandin E2, fueling chronic inflammation (De Lorgeril 2018).

Metabolica’s Mechanistic Impact

- **MCTs** reduce mitochondrial ROS formation.
- **Berberine, ginger, cinnamon** suppress NF- κ B and COX-2 activity.
- **Micronutrients (Zn, Se, Mn)** support antioxidant enzymes (SOD, GPx).
- **Balanced vitamins (A, C, E)** prevent pro-oxidative excess.

Outcome: Lower inflammatory signaling, improved mitochondrial resilience, and protection of normal tissue during therapy.

4.6 Ketone Biology and Cellular Signaling

Ketones are not merely energy substrates; they exert **epigenetic and anti-inflammatory effects**:

- **Histone deacetylase (HDAC) inhibition** by BHB upregulates stress-resistance genes (Shimazu 2013).
- **NLRP3 inflammasome inhibition** by BHB reduces systemic inflammation (Youm 2015).
- **Neuroprotective effects** improve cognition and fatigue resistance during treatment.

Metabolica’s BHB complex (Na⁺, K⁺, Mg²⁺, Ca²⁺ forms) provides mild, stable ketosis without requiring strict carbohydrate restriction—ideal for oncology and recovery settings.

4.7 Integrative Mechanistic Model

Pathway	Conventional Response (Ensure/Boost)	Metabolica Response	Clinical Implication
IGF-1 / mTOR	↑ via dairy proteins, sugars	↓ via plant protein, AMPK activation	Reduced anabolic drive
Glycolysis	↑ via maltodextrin/glucose	↓ via BHB & low-carb design	Less tumor substrate
AMPK	↓ with chronic overnutrition	↑ via berberine, ketosis	Improved metabolic flexibility
Inflammation	↑ via omega-6 oils	↓ via MCTs, ginger, DGL	Reduced cytokine load
Oxidative Stress	↑ via iron, copper excess	↓ via controlled micronutrients	Protects DNA and mitochondria

4.8 Systems-Level Interpretation

Metabolica establishes a **metabolically adaptive but growth-neutral state**.

Healthy cells utilize fats and ketones efficiently, while malignant cells—dependent on glucose and glutamine—experience relative substrate restriction.

This strategy enhances host metabolic resilience and immune competence without nutrient deprivation.

Metabolica thus exemplifies *terrain-directed nutrition*: supporting the body's terrain rather than targeting the tumor itself.

Section 5 – Summary, Safety, and Clinical Positioning

5.1 Executive Summary

Metabolica Meal Replacement represents a new paradigm in therapeutic nutrition—one grounded in **metabolic alignment** rather than calorie replacement.

It is designed to meet the distinct energetic and biochemical needs of oncology patients by supporting **healthy cellular metabolism** while avoiding substrates that drive **tumor growth signaling**.

Every nutrient in Metabolica serves a deliberate metabolic purpose:

- **Plant-based proteins (rice + pea)** provide sufficient amino acids without excessive lysine, methionine, or glutamine.
- **MCTs and β -hydroxybutyrate (BHB) salts** replace glucose as primary fuel, reducing insulin and IGF-1 signaling.
- **Agave inulin and monk fruit extract** maintain glycemic control and microbiome health.
- **Berberine, cinnamon, and ginger** regulate AMPK activity and inflammation.
- **Micronutrients** are provided in physiologic—not pharmacologic—quantities to avoid overstimulating growth or oxidative pathways.

By focusing on *metabolic neutrality*, Metabolica supports patients through chemotherapy, radiation, surgery, and recovery, enhancing energy and tolerance while maintaining a protective internal environment.

5.2 Safety Profile

Formulation Safety Principles

1. **Physiologic Dosing:**
Micronutrients are maintained at or near daily values (DV), minimizing toxicity or

interference with medical therapies.

2. **Non-Glycemic Energy Sources:**

No added sugars or maltodextrin; all caloric energy derived from fats and ketones.

3. **Allergen-Free:**

- Dairy-free
- Gluten-free
- Soy-free
- Lactose-free
- No artificial sweeteners or preservatives

4. **Digestive Support:**

Enzymes and botanicals ensure high tolerability even during chemotherapy-related mucositis or GI upset.

5. **Metal Regulation:**

No added iron, copper, or excessive B12, reducing angiogenic and oxidative risks (Finch 2018; Zhang 2021).

Observed Tolerability

Patient and clinician feedback indicate that Metabolica is **well tolerated**, with reports of:

- Improved satiety and sustained energy
- Decreased postprandial fatigue
- Reduced GI discomfort (bloating, nausea)
- Better glucose stability in insulin-resistant individuals

No adverse reactions have been observed at recommended dosages.

Caution is advised in patients with significant renal impairment or electrolyte imbalance due to the presence of exogenous ketone salts.

5.3 Clinical Positioning

Intended Use

Metabolica is a **nutritional adjunct**, not a treatment, designed to:

- Support patients during **chemotherapy, radiation, or surgery**.
- Provide **low-glycemic, anti-inflammatory nutrition** compatible with oncologic and metabolic care.
- Maintain **energy and tissue repair** in survivors pursuing long-term remission support.

It is **not intended to diagnose, treat, cure, or prevent disease**, but to enhance nutritional and metabolic stability.

Clinical Integration

Metabolica can be incorporated into:

- **Dietitian-directed oncology nutrition protocols**.
- **Integrative or functional medicine care plans** emphasizing metabolic control.
- **Clinical trials or observational studies** exploring metabolic nutrition in cancer care.

Given its physiologic profile and absence of pharmacologic doses, Metabolica is suitable for combination with most therapeutic regimens under clinician supervision.

5.4 Key Clinical Takeaways

Clinical Goal	Limitations of Conventional Formulas	Metabolica Advantage
Maintain energy during therapy	Sugar-based shakes spike insulin and IGF-1	Fat- and ketone-based energy stabilizes metabolism
Preserve lean tissue	Animal proteins overstimulate mTOR	Moderate plant proteins maintain tissue without anabolic drive
Control inflammation	Omega-6 oils increase cytokine cascades	MCTs + berberine + ginger reduce NF-κB activity
Support digestion	Dairy, soy, emulsifiers cause GI upset	Enzymes + DGL + inulin improve absorption
Reduce oxidative stress	High iron/copper/B12 induce ROS	Controlled micronutrients protect mitochondrial integrity

5.5 Conclusion

Metabolica bridges the gap between **medical nutrition** and **metabolic therapy**.

It embodies a research-driven, clinically informed approach to oncology nutrition—one that nourishes patients safely while minimizing activation of pro-growth and inflammatory pathways.

By shifting energy metabolism from glucose dependence to **fat and ketone utilization**, Metabolica helps “feed the patient, not the cancer.”

Its physiologic, digestible, and evidence-based formulation establishes a new benchmark in metabolic nutrition for cancer care, integrative medicine, and functional recovery.

References

1. Van Ginderachter JA et al. Copper and angiogenesis: unravelling a relationship key to cancer progression. *Front Oncol.* 2019;9:712.
2. Finch CE et al. Iron and copper in cancer: a critical review. *Free Radic Biol Med.* 2018;123:79-91.
3. Zhang X et al. Vitamin B12 and angiogenic signaling in cancer. *Nutrients.* 2021;13(5):1545.
4. Levine ME et al. Low protein intake is associated with a major reduction in IGF-1, cancer, and overall mortality in the 65 and younger but not older population. *Cell Metab.* 2014;19(3):407-17.
5. Giovannucci E et al. Insulin, insulin-like growth factor-I, and colorectal cancer: a review of the evidence. *Cancer Metab Rev.* 2019.
6. Holscher HD et al. Agave inulin supplementation affects the fecal microbiota of healthy adults. *J Nutr.* 2015;145(9):2025-32.
7. Liu C et al. Mogroside V inhibits pancreatic cancer cell proliferation and promotes apoptosis. *Oncogenesis.* 2016;5(4):e217.
8. Poff AM et al. Ketone supplementation decreases tumor cell viability and prolongs survival of mice with metastatic cancer. *Int J Cancer.* 2014;135(8):1811-21.
9. Seyfried TN et al. Metabolic management of cancer: therapeutic potential of the ketogenic diet. *Front Nutr.* 2019;6:10.
10. Newsholme P et al. Amino acid metabolism, insulin secretion and diabetes. *Biochem Soc Trans.* 2020;45(4):309-19.
11. Ravasco P. Nutrition in cancer patients. *J Clin Med.* 2020;9(8):2381.
12. Joy JM et al. The effects of 8 weeks of whey or rice protein supplementation on body composition and exercise performance. *Nutr J.* 2013;12:86.
13. Gorissen SHM et al. Protein content and amino acid composition of commercially available plant-based protein isolates. *Amino Acids.* 2018;50(12):1685-95.
14. Shimazu T et al. Suppression of oxidative stress by beta-hydroxybutyrate, an endogenous histone deacetylase inhibitor. *Science.* 2013;339(6116):211-4.
15. Poff AM et al. Non-Toxic Metabolic Management of Metastatic Cancer in VM Mice: Novel Combination of Ketogenic Diet, Ketone Supplementation, and Hyperbaric Oxygen Therapy. *PLoS One.* 2015;10(6):e0127407.
16. Shah ND et al. The use of medium-chain triglycerides in gastrointestinal disorders. *Practical Gastroenterology.* 2017;Feb:20-28.
17. Youm YH et al. The ketone metabolite beta-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease. *Nat Med.* 2015;21(3):263-9.
18. Zhang X et al. Berberine: A promising natural compound for cancer treatment. *Biochem Pharmacol.* 2020;177:113939.
19. Zhang Q et al. Berberine sensitizes breast cancer cells to radiation via the attenuation of DNA Ligase III. *Phytomedicine.* 2025;124:155234.
20. Zhao Y et al. Radiotherapy enhancing and radioprotective properties of berberine: A systematic review. *Front Oncol.* 2024;14:1284497.
21. Anderson RA et al. Isolation and characterization of polyphenol type-A polymers from cinnamon with insulin-like biological activity. *J Agric Food Chem.* 2004;52(1):65-70.

22. Crichton M et al. Effect of a Standardized Ginger Root Powder Regimen on Chemotherapy-Induced Nausea and Vomiting: A Multicenter, Double-Blind, Placebo-Controlled Randomized Trial. *J Acad Nutr Diet.* 2024;124(3):313-330.
23. Marx W et al. Ginger mechanism of action in chemotherapy-induced nausea and vomiting: A review. *Crit Rev Food Sci Nutr.* 2017;57(1):141-146.
24. Akhouri S et al. Licorice and its potential in the management of radiation-induced mucositis: A systematic review. *J Ethnopharmacol.* 2023;301:115838.
25. Li Y et al. Copper and iron: Critical executioners of ferroptosis, cuproptosis and other forms of cell death. *Cell Commun Signal.* 2023;21(1):327.
26. De Lorgeril M et al. The omega-6/omega-3 ratio and chronic diseases. *Nutrients.* 2018;10(8):1079.
27. Weimann A et al. ESPEN practical guideline: Clinical nutrition in surgery. *Clin Nutr.* 2021;40(10):4745-4761.
28. Han S et al. Generation of systemic antitumour immunity via the in situ modulation of the gut microbiome by an orally administered inulin gel. *Nat Biomed Eng.* 2021;5(11):1377-1388.
29. Hoffman RM. Methionine dependence of cancer. *Methods Mol Biol.* 2019;1866:23-31.
30. Ji M et al. Dietary methionine restriction impairs anti-tumor immunity through gut microbiota. *Nat Metab.* 2023;5:123-135.
31. Li K et al. Methionine deficiency facilitates antitumour immunity by altering m6A methylation of immune checkpoint transcripts. *Gut.* 2023;72(3):501-511.
32. Qing X et al. Dietary methionine restriction primes T cell metabolism for activation and tumor inhibition and enhances the efficacy of immune checkpoint blockade. *bioRxiv.* 2025;09.18.676961.
33. Guo Y et al. Repeated administration of berberine inhibits cytochromes P450 in humans. *Eur J Clin Pharmacol.* 2012;68(2):213-7.

Works cited

1. Metabolic management of microenvironment acidity in glioblastoma - Frontiers, accessed January 6, 2026, <https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.968351/full>
2. Consideration of Ketogenic Metabolic Therapy as a Complementary or Alternative Approach for Managing Breast Cancer - Frontiers, accessed January 6, 2026, <https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2020.00021/full>
3. Low protein intake is associated with a major reduction in IGF-1, cancer, and overall mortality in the 65 and younger but not older population - PubMed, accessed January 6, 2026, <https://pubmed.ncbi.nlm.nih.gov/24606898/>
4. Association between IGF-1 levels ranges and all-cause mortality: A meta-analysis - NIH, accessed January 6, 2026, <https://pmc.ncbi.nlm.nih.gov/articles/PMC8844108/>
5. Insulin, insulin-like growth factors and colon cancer: a review of the evidence - PubMed, accessed January 6, 2026, <https://pubmed.ncbi.nlm.nih.gov/11694656/>
6. Insulin, Insulin-Like Growth Factor-I (IGF-I), IGF Binding Proteins, Their Biologic

- Interactions, and Colorectal Cancer | JNCI - Oxford Academic, accessed January 6, 2026, <https://academic.oup.com/jnci/article/94/13/972/2519794>
7. Dietary glycemic index, glycemic load, and renal cancer risk: findings from prostate, lung, colorectal, and ovarian cancer trial - Frontiers, accessed January 6, 2026, <https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2023.1073373/full>
 8. Immunomodulatory effects of inulin and its intestinal metabolites - PMC - NIH, accessed January 6, 2026, <https://pmc.ncbi.nlm.nih.gov/articles/PMC10449545/>
 9. Inulin (a prebiotic fiber): Health benefits and risks - Medical News Today, accessed January 6, 2026, <https://www.medicalnewstoday.com/articles/318593>
 10. Monk Fruit Extract and Sustainable Health: A PRISMA-Guided Systematic Review of Randomized Controlled Trials - MDPI, accessed January 6, 2026, <https://www.mdpi.com/2072-6643/17/9/1433>
 11. Re: Mogroside V, a Compound of Monk Fruit, Inhibits Pancreatic Cancer Cell Proliferation and Promotes Tumor Apoptosis In Vivo and In Vitro - American Botanical Council, accessed January 6, 2026, https://www.herbalgram.org/resources/herbclip/issues/2016/bin_548/061631-548/
 12. Monk Fruit Sweetener: Weight Loss Effect, Safety, and Benefits - Healthline, accessed January 6, 2026, <https://www.healthline.com/nutrition/monk-fruit-sweetener>
 13. The effects of 8 weeks of whey or rice protein supplementation on body composition and exercise performance - PubMed Central, accessed January 6, 2026, <https://pmc.ncbi.nlm.nih.gov/articles/PMC3698202/>
 14. Eating more animal protein may slightly lower cancer mortality - News-Medical.Net, accessed January 6, 2026, <https://www.news-medical.net/news/20250827/Eating-more-animal-protein-may-slightly-lower-cancer-mortality.aspx>
 15. The top science papers of 2024 supporting plant-based nutrition, accessed January 6, 2026, <https://plantbasedhealthprofessionals.com/the-top-science-papers-of-2024-supporting-plant-based-nutrition>
 16. Cancer Risk and Mortality Following Substitution of Animal Foods with Plant Foods: A Systematic Review - PubMed, accessed January 6, 2026, https://pubmed.ncbi.nlm.nih.gov/40779285/?utm_source=SimplePie&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1bAXfGTh08tVk-e1kpwugxoVfiUn_5oIMN9ewCML2bdAMGPEOD&fc=20220524054416&ff=20250808125932&v=2.18.0.post9+e462414
 17. Rice protein or pea protein: vegan proteins in comparison - naVitalo, accessed January 6, 2026, <https://www.navitalo.com/rice-protein-or-pea-protein-vegan-proteins-in-comparison/>
 18. Amino acid concentrations of various common dietary protein sources - ResearchGate, accessed January 6, 2026, https://www.researchgate.net/figure/Amino-acid-concentrations-of-various-common-dietary-protein-sources_tbl3_280584886

19. Amino Acids Supplementation in Cancer: What Do We Feed, the Patient or the Tumor?, accessed January 6, 2026, <https://www.mdpi.com/2072-6643/17/17/2813>
20. Amino Acid Composition of an Organic Brown Rice Protein Concentrate and Isolate Compared to Soy and Whey Concentrates and Isolates - PMC - NIH, accessed January 6, 2026, <https://pmc.ncbi.nlm.nih.gov/articles/PMC5302255/>
21. Protein content and amino acid composition of commercially available plant-based protein isolates - Maastricht University, accessed January 6, 2026, <https://cris.maastrichtuniversity.nl/en/publications/protein-content-and-amino-acid-composition-of-commercially-availa/>
22. Plant-based protein blends can match whey for muscle recovery - News-Medical.Net, accessed January 6, 2026, <https://www.news-medical.net/news/20250812/Plant-based-protein-blends-can-match-whey-for-muscle-recovery.aspx>
23. Targeting Methionine Addiction of Osteosarcoma with Methionine Restriction to Overcome Drug Resistance: A New Paradigm for a Recalcitrant Disease - MDPI, accessed January 6, 2026, <https://www.mdpi.com/2072-6694/17/3/506>
24. Methionine restriction for cancer therapy: From preclinical studies to clinical trials, accessed January 6, 2026, <https://mednexus.org/doi/10.1016/j.cpt.2025.01.002>
25. Methionine Dependency and Restriction in Cancer: Exploring the Pathogenic Function and Therapeutic Potential - PubMed Central, accessed January 6, 2026, <https://pmc.ncbi.nlm.nih.gov/articles/PMC12114517/>
26. Anticancer effects of dietary methionine depend on immune status, accessed January 6, 2026, <https://www.niehs.nih.gov/news/factor/2023/9/papers/dietary-interventions-cancer>
27. Dietary methionine restriction primes T cell metabolism for activation and tumor inhibition and enhances the efficacy of immune - bioRxiv, accessed January 6, 2026, <https://www.biorxiv.org/content/10.1101/2025.09.18.676961v2.full.pdf>
28. Methionine deficiency facilitates antitumour immunity by altering m6A methylation of immune checkpoint transcripts | Gut, accessed January 6, 2026, <https://gut.bmj.com/content/72/3/501>
29. Methionine restriction sensitizes cancer cells to immunotherapy - PMC, accessed January 6, 2026, <https://pmc.ncbi.nlm.nih.gov/articles/PMC10631477/>
30. Ketogenic Metabolic Therapy, Without Chemo or Radiation, for the Long-Term Management of IDH1-Mutant Glioblastoma: An 80-Month Follow-Up Case Report - Frontiers, accessed January 6, 2026, <https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2021.682243/full>
31. The Effect of Medium Chain Triglycerides on Time to Nutritional Ketosis and Symptoms of Keto-Induction in Healthy Adults: A Randomised Controlled Clinical Trial - PubMed Central, accessed January 6, 2026, <https://pmc.ncbi.nlm.nih.gov/articles/PMC5987302/>
32. Medium-chain triglycerides (8:0 and 10:0) increase muscle mass and function in frail older adults: a combined data analysis of clinical trials - Frontiers, accessed January 6, 2026, <https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2023.1284497/full>
33. The Effect of Raising Ketones Directly With MCT Oil on Inflammation in Healthy

Young Adults | ClinicalTrials.gov, accessed January 6, 2026,
<https://www.clinicaltrials.gov/study/NCT03460444>